Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat
Journal of Basic and Clinical Physiology and Pharmacology · 2024
DOI: 10.1515/jbcpp-2023-0254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Basic and Clinical Physiology and Pharmacology, 2024. Verfasst von Oishani Chatterjee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacology, Guru Nanak Institute of Pharmaceutical Science and Technology, Kolkata, India. Hauptthemen laut MEDLINE: Psoriasis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objectives
Psoriasis is a persistent autoimmune inflammatory condition that is primarily affecting the skin. Pioglitazone (PGZ), a peroxisome proliferator activated receptor gamma (PPARγ) agonist, has been reported to have anti-inflammatory effects. However, the role of PGZ in psoriatic disease remains unclear. In this study, we aimed to repurpose the use of the PGZ for the treatment of psoriasis.
Methods
To investigate its efficacy, we employed an imiquimod (IMQ)-induced rat model. Wistar rats are randomly allocated to four different groups. Group, I served as a negative control, Group II IMQ control, Group III was treated with pioglitazone hydrogel and Group IV received standard drug betamethasone cream. PASI score was monitored on every alternative day and on day 7 animals were sacrificed and histopathology of skin was performed. Level of nitric oxide (NO) and myeloperoxidase (MPO) was also performed using established methods.
Results
The results of the experiment revealed that treatment with PGZ significantly (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacology, Guru Nanak Institute of Pharmaceutical Science and Technology, Kolkata, India.
ORCID-Profile: Debjeet Sur
Zitieren
APA
Chatterjee, O., & Sur, D. (2024). Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat. Journal of Basic and Clinical Physiology and Pharmacology. https://doi.org/10.1515/jbcpp-2023-0254
Vancouver
Chatterjee O, Sur D. Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat. Journal of Basic and Clinical Physiology and Pharmacology. 2024. doi:10.1515/jbcpp-2023-0254
BibTeX
@article{Chatterjee2024,
author = {Chatterjee, Oishani and Sur, Debjeet},
title = {Pioglitazone attenuate level of myeloperoxidases and nitic oxide in psoriatic lesion: a proof-of-concept study in a imiquimod induced psoriasis model in rat},
journal = {Journal of Basic and Clinical Physiology and Pharmacology},
year = {2024},
doi = {10.1515/jbcpp-2023-0254}
}
EUVIMED